Rapid Quantification of Vincristine in Mouse Plasma Using ESI-LC-MS/MS: Application to Pharmacokinetic Studies
Overview
Chemistry
Affiliations
A simple, rapid, and sensitive LC-MS/MS method for determining concentrations of the anticancer alkaloid vincristine in micro volumes of mouse plasma was developed and validated in positive ion mode. Separation of vincristine and the internal standard [H]-vincristine was achieved on an Accucore aQ column with a gradient mobile phase delivered at a flow rate of 0.4 mL/min and a run time of 2.2 min. Calibration curves were linear (r > 0.99, n = 8) up to 250 ng/mL, with a lower limit of quantitation of 2.5 ng/mL. The matrix effect and extraction recovery for vincristine were ranging 108-110% and 88.4-107%, respectively. The intra-day and inter-day precision of quality controls tested at 3 different concentrations were always less than 15%, and accuracy ranged from 91.7 to 107%. The method was successfully applied to evaluate the pharmacokinetic profile of vincristine in wild-type and CYP3A-deficient mice in support of a project to provide mechanistic insight into drug-drug interactions and to identify sources of inter-individual pharmacokinetic variability associated with vincristine-induced peripheral neuropathy.
Pharmacokinetics, bioavailability and tissue distribution of chitobiose and chitotriose in rats.
Chen M, Jin J, Ji X, Chang K, Li J, Zhao L Bioresour Bioprocess. 2024; 9(1):13.
PMID: 38647841 PMC: 10991139. DOI: 10.1186/s40643-022-00500-y.
Vincristine Disposition and Neurotoxicity Are Unchanged in Humanized CYP3A5 Mice.
Li Y, Kazuki Y, Drabison T, Kobayashi K, Fujita K, Xu Y Drug Metab Dispos. 2023; 52(2):80-85.
PMID: 38071551 PMC: 10801630. DOI: 10.1124/dmd.123.001466.
Targeting a xenobiotic transporter to ameliorate vincristine-induced sensory neuropathy.
Li Y, Drabison T, Nepal M, Ho R, Leblanc A, Gibson A JCI Insight. 2023; 8(14).
PMID: 37347545 PMC: 10443802. DOI: 10.1172/jci.insight.164646.
Development of the DNA-based voltammetric biosensor for detection of vincristine as anticancer drug.
Abbasi M, Alsaikhan F, Obaid R, Jahani S, Biroudian S, Oveisee M Front Chem. 2023; 10:1060706.
PMID: 36700073 PMC: 9870317. DOI: 10.3389/fchem.2022.1060706.
Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neurotoxicity.
Nepal M, Taheri H, Li Y, Talebi Z, Uddin M, Jin Y Cancer Res Commun. 2022; 2(11):1334-1343.
PMID: 36506732 PMC: 9730833. DOI: 10.1158/2767-9764.crc-22-0172.